Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q1 2026 · 10-Q
Revenue$0.00$0.00— vs Q1 2025 Net Income-$113.72K-$113.72KN/M vs Q1 2025 EPS Diluted$0.00$0.00N/M vs Q1 2025 Operating Income-$64,002N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
ended Nov 30, 2025 · filed Jan 14, 2026 · 45 d after period end